Pipeline Progress: Evopoint Received Approval for Its Oral Protein Degrader XNW34017 for Clinical Trials
2025/11/08
On November 8, 2025, Evopoint Biosciences, a disease-oriented biopharmaceutical company dedicated to addressing significant unmet clinical needs worldwide by translating
innovation into clinical value and providing the best therapeutic solutions for patients globally, announced the approval of XNW34017, an independently-developed oral protein
degrader XNW34017 by Evopoint, by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate clinical trials. The company will soon
launch a Phase I clinical study of XNW34017 in patients with advanced solid tumors.XNW34017 is a first-in-class, oral protein degrader targeting AURKA while simultaneously degrading
MYC. Preclinical studies have demonstrated its excellent therapeutic potential across multiple malignant tumors.
Jason Le, CEO of Evopoint
innovation into clinical value and providing the best therapeutic solutions for patients globally, announced the approval of XNW34017, an independently-developed oral protein
degrader XNW34017 by Evopoint, by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate clinical trials. The company will soon
launch a Phase I clinical study of XNW34017 in patients with advanced solid tumors.XNW34017 is a first-in-class, oral protein degrader targeting AURKA while simultaneously degrading
MYC. Preclinical studies have demonstrated its excellent therapeutic potential across multiple malignant tumors.
Jason Le, CEO of Evopoint
"XNW34017 is developed with our proprietary next-generation targeted protein degradation (TPD) platform which is designed to unlock conventionally 'undruggable' targets and develop
highly selective, orally bioavailable protein degraders. By leveraging this platform, we aim to establish a product pipeline with potent anti-tumor efficacy and significantly improved therapeutic
window, thereby broadening treatment options and improving clinical benefits for cancer patients. As the platform continues to advance, we plan to develop multiple differentiated TPD
candidates, expand our product portfolio, and further promote the progress of precision oncology.”
Previous
Next
